Department of Health and Social Care written question – answered at on 26 January 2026.
Dr Caroline Johnson
Shadow Minister (Health and Social Care)
To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure access to CAR-T therapy for mantle cell lymphoma patients who previously have been ineligible under the cancer drugs fund following NICE's most recent decision.
Zubir Ahmed
The Parliamentary Under-Secretary for Health and Social Care
Decisions on whether new medicines should be routinely funded by the National Health Service in England are made by the National Institute for Health and Care Excellence (NICE) on the basis of an evaluation of their costs and benefits. NICE is currently re-evaluating brexucabtagene autoleucel (Tecartus) to determine whether it can be recommended for routine NHS use, taking into account real-world evidence generated through its use in the Cancer Drugs Fund.
NICE has been unable to recommend the treatment in the final draft guidance, which is available at the following link:
https://www.nice.org.uk/guidance/indevelopment/gid-ta11545/documents
This is because the available evidence does not suggest that brexucabtagene autoleucel is value for money in this population. Final guidance has not yet been published and the period to appeal NICE’s final draft recommendations closed on 19 January.
In line with an arrangement between NHS England and the company, if NICE’s final guidance does not recommend use, patients who started treatment during the managed access period can continue their treatment.
Yes0 people think so
No0 people think not
Would you like to ask a question like this yourself? Use our Freedom of Information site.
Secretary of State was originally the title given to the two officials who conducted the Royal Correspondence under Elizabeth I. Now it is the title held by some of the more important Government Ministers, for example the Secretary of State for Foreign Affairs.
